You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 22, 2024

JEVTANA KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Jevtana Kit, and when can generic versions of Jevtana Kit launch?

Jevtana Kit is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-six patent family members in forty-six countries.

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cabazitaxel profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Jevtana Kit

A generic version of JEVTANA KIT was approved as cabazitaxel by ACCORD HLTHCARE on December 29th, 2021.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for JEVTANA KIT?
  • What are the global sales for JEVTANA KIT?
  • What is Average Wholesale Price for JEVTANA KIT?
Drug patent expirations by year for JEVTANA KIT
Recent Clinical Trials for JEVTANA KIT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrew J. Armstrong, MDPhase 2
Janssen PharmaceuticaPhase 2
OHSU Knight Cancer InstitutePhase 1

See all JEVTANA KIT clinical trials

Paragraph IV (Patent) Challenges for JEVTANA KIT
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
JEVTANA KIT Injection cabazitaxel 60 mg/1.5 mL 201023 8 2014-06-17

US Patents and Regulatory Information for JEVTANA KIT

JEVTANA KIT is protected by four US patents.

Patents protecting JEVTANA KIT

Antitumoral use of cabazitaxel
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-AGONIST

Antitumoral use of cabazitaxel
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST

Acetone solvate of dimethoxy docetaxel and its process of preparation
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Antitumoral use of cabazitaxel
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for JEVTANA KIT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us JEVTANA KIT cabazitaxel SOLUTION;INTRAVENOUS 201023-001 Jun 17, 2010 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for JEVTANA KIT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Accord Healthcare S.L.U. Cabazitaxel Accord cabazitaxel EMEA/H/C/005178
Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Authorised yes no no 2020-08-28
Sanofi Winthrop Industrie Jevtana cabazitaxel EMEA/H/C/002018
Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Authorised no no no 2011-03-17
Teva B.V. Cabazitaxel Teva cabazitaxel EMEA/H/C/004951
Treatment of prostate cancer
Refused no no no 2019-07-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for JEVTANA KIT

See the table below for patents covering JEVTANA KIT around the world.

Country Patent Number Title Estimated Expiration
Peru 51097 NUEVOS TAXOIDES, SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN ⤷  Sign Up
Austria 188471 ⤷  Sign Up
Yugoslavia 67692 ⤷  Sign Up
Mexico 9400806 PROCESO PARA LA PREPARACION DE DERIVADOS DE TAXANO E INTERMEDIARIO ß-LACTAMA PARA LOS MISMOS. ⤷  Sign Up
Slovakia 279946 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 9300928 ⤷  Sign Up
Morocco 33767 استخدام جديد لكبازيتكسيل مضاد لسرطان ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for JEVTANA KIT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1667986 28/2013 Austria ⤷  Sign Up PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986 C20130017 00077 Estonia ⤷  Sign Up PRODUCT NAME: KABASITAKSEEL;REG NO/DATE: K(2011)1888 LOPLIK 17.03.2011
1667986 C300595 Netherlands ⤷  Sign Up PRODUCT NAME: CABAZITAXEL ACETONAAT; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986 PA2013010 Lithuania ⤷  Sign Up PRODUCT NAME: CABAZITAXELUM; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1667986 C 2013 017 Romania ⤷  Sign Up PRODUCT NAME: SOLVAT ACETONIC DE CABAZITAXEL; NATIONAL AUTHORISATION NUMBER: EU/1/11/676/001; DATE OF NATIONAL AUTHORISATION: 20110317; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/676/001; DATE OF FIRST AUTHORISATION IN EEA: 20110317
1667986 92172 Luxembourg ⤷  Sign Up PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
1667986 636 Finland ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.